knownwell at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
knownwell brings 15 presentations to ObesityWeek 2026 in National Harbor. Its program centers on rethinking treatment success through body composition and on the obesity treatment journey, from discontinuation and telemedicine care to Medicare and Medicaid coverage. Posters report extra weight loss after switching from semaglutide to tirzepatide and why some adults decline GLP-1 therapy.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
Obesity medicine and weight-inclusive primary care provider with virtual visits nationwide and in-person clinics in several states. | Session Sat Nov 14 8:30am–12:00pm The Obesity Society's Best Practices in Obesity Management: Live at ObesityWeek 2026 Clinicians work through patient cases on screening, assessing complications and building treatment plans, including choosing and adjusting obesity drugs. Clinical obesity care and professional practiceObesity pharmacotherapy and drug developmentBariatric surgery and devicesChronic disease and obesity complications Talk Sat Nov 14 11:45am–1:15pm Rethinking Success in the Treatment of Overweight and Obesity Through Body Composition: What Are We Made of? Asks whether body composition, not weight loss alone, should measure obesity treatment success, and reviews activin E biology and small interfering RNA drugs. Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 11:55am–12:10pm Changing the Treatment Paradigm in Overweight and Obesity Management Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 12:10pm–12:35pm Beyond The Scale: The Clinical Relevance of Body Composition, Body Fat Distribution and Lean Mass Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 1:00pm–1:10pm The Next Frontier: How May New Therapies for Overweight and Obesity Impact Body Composition? Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 1:10pm–1:15pm Rethinking Success: Where Should Obesity Treatment Go? Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sun Nov 15 7:30am–8:30am The Obesity Treatment Journey: Evaluating Burden, Discontinuation, and Outcomes Uses a patient case and real-world data to examine why patients stop obesity treatment, what follows, and care changes that keep people on therapy. Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practicePolicy and public healthNutrition, diet and foodChronic disease and obesity complicationsNeuroscience of appetite and eatingObesity pharmacotherapy and drug development Session Sun Nov 15 9:30am–10:30am Talk Sun Nov 15 11:45am–1:15pm Bridging Obesity and MASLD Through Metabolic Dysfunction Links obesity, visceral and liver fat, and MASLD, making the case for waist measures and early liver checks, with patients describing their own experience. Metabolism and integrative physiologyChronic disease and obesity complications Talk Sun Nov 15 11:45am–1:15pm Treating Obesity First: Exploring the Role of Amylin Analogues in the Future of Obesity Care Reviews trial data on amylin analogues, which act through a different hormone pathway than GLP-1, as single or combination obesity treatments. Interventional and clinical studiesNutrition, diet and food Talk Sun Nov 15 2:45pm–3:15pm Talk Sun Nov 15 5:20pm–5:40pm Who’s Covered by the Feds? Access to Obesity Medications in Medicare and Medicaid Policy and public healthObesity pharmacotherapy and drug development Talk Mon Nov 16 11:45am–1:15pm Discover Zepbound (Tirzepatide) Injection Reviews efficacy, safety and dosing evidence for tirzepatide injection and how to identify adult patients who may be suitable for it. Metabolism and integrative physiologyPopulation health and epidemiologyNutrition, diet and foodObesity pharmacotherapy and drug development Poster Mon Nov 16 2:30pm–3:30pm Why Adults With Obesity Decline GLP-1 Therapy: Preference for Limited Medication Exposure Population health and epidemiology Poster Mon Nov 16 2:30pm–3:30pm Additional Weight Loss After Switching From Semaglutide to Tirzepatide in Real-World Obesity Care Population health and epidemiology |
Find decision makers at knownwell
Tell us what you sell and we’ll find the people at knownwell most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction